These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 26177348

  • 1. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
    Liu LS, Li J, Chen XT, Zhang HX, Fu Q, Wang HY, Xiong YY, Liu S, Liu XM, Li JL, Huang M, Wang CX.
    Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
    [Abstract] [Full Text] [Related]

  • 2. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
    Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, Mourad M, Kuypers DR, Haufroid V, van Gelder T, van Schaik RH.
    Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
    [Abstract] [Full Text] [Related]

  • 3. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 4. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
    Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R.
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug; 380(2):169-77. PubMed ID: 19343327
    [Abstract] [Full Text] [Related]

  • 5. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
    Ghafari S, Dashti-Khavidaki S, Khatami MR, Ghahremani MH, Seyednejad SA, Beh-Pajooh A.
    Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
    [Abstract] [Full Text] [Related]

  • 6. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
    Yang TH, Chen YK, Xue F, Han LZ, Shen CH, Zhou T, Luo Y, Zhang JJ, Xia Q.
    Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
    [Abstract] [Full Text] [Related]

  • 7. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P, Li J, Li J, Deng R, Fu Q, Chen J, Huang M, Chen X, Wang C.
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [Abstract] [Full Text] [Related]

  • 8. Influence of CYP3A5 Genetic Polymorphism on Long-Term Renal Function in Chinese Kidney Transplant Recipients Using Limited Sampling Strategy and Abbreviated Area Under the Curve for Tacrolimus Monitoring.
    Cheung CY, Chan KM, Wong YT, Chak WL, Bekers O, van Hooff JP.
    Prog Transplant; 2020 Sep; 30(3):249-253. PubMed ID: 32552577
    [Abstract] [Full Text] [Related]

  • 9. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M.
    Transplantation; 2012 Nov 27; 94(10):1013-9. PubMed ID: 23073468
    [Abstract] [Full Text] [Related]

  • 10. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
    Ro H, Min SI, Yang J, Moon KC, Kim YS, Kim SJ, Ahn C, Ha J.
    Ther Drug Monit; 2012 Dec 27; 34(6):680-5. PubMed ID: 23149441
    [Abstract] [Full Text] [Related]

  • 11. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul 27; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 12. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A.
    Transplant Proc; 2008 Jun 27; 40(5):1690-5. PubMed ID: 18589174
    [Abstract] [Full Text] [Related]

  • 13. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
    Cheng Y, Li H, Meng Y, Liu H, Yang L, Xu T, Yu J, Zhao N, Liu Y.
    Int J Clin Pract Suppl; 2015 May 27; (183):16-22. PubMed ID: 26177012
    [Abstract] [Full Text] [Related]

  • 14. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, Suarez-Kurtz G.
    Pharmacogenomics; 2011 Sep 27; 12(9):1293-303. PubMed ID: 21806386
    [Abstract] [Full Text] [Related]

  • 15. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug 27; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 16. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
    Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA.
    Clin Transplant; 2018 Dec 27; 32(12):e13424. PubMed ID: 30318646
    [Abstract] [Full Text] [Related]

  • 17. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
    Chen SY, Li JL, Meng FH, Wang XD, Liu T, Li J, Liu LS, Fu Q, Huang M, Wang CX.
    Clin Transplant; 2013 Dec 27; 27(3):E272-81. PubMed ID: 23432535
    [Abstract] [Full Text] [Related]

  • 18. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
    Chen Z, Cheng X, Zhang L, Tang L, Fang Y, Chen H, Zhang L, Shen A.
    Pharmacol Rep; 2021 Oct 27; 73(5):1418-1426. PubMed ID: 34089513
    [Abstract] [Full Text] [Related]

  • 19. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
    Yanik MV, Seifert ME, Locke JE, Hauptfeld-Dolejsek V, Crowley MR, Cutter GR, Mannon RB, Feig DI, Limdi NA.
    Pediatr Transplant; 2019 Aug 27; 23(5):e13494. PubMed ID: 31124575
    [Abstract] [Full Text] [Related]

  • 20. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K, Kolsi A, Kerkeni E, Ben Fredj N, Chaabane A, Monastiri K, Boughattas N.
    Pharmacogenomics; 2015 Dec 27; 16(18):2045-54. PubMed ID: 26615671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.